Colorectal Cancer Pipeline Therapeutic Review H1 2017
For More on Colorectal Cancer Pipeline Review H1 2017 Report Inquire @
Pharmaceutical guide Colorectal Cancer - Pipeline Review H1 2017 guide reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 25, 108, 137, 10, 173, 26 and 10 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 18, 9, 28 and 5 molecules, respectively. Report provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Get Discount On Report@ https://goo.gl/M9PnW9 .
Report Includes Colorectal Cancer Pipeline by:
2cureX ApS, 3-V Biosciences Inc, 3SBio Inc, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Adamed Sp z oo, Aduro BioTech Inc, Advenchen Laboratories LLC, Alchemia Ltd, Allinky Biopharma, amcure GmbH, Amgen Inc, Antibe Therapeutics Inc, APEIRON Biologics AG, Apexigen Inc, Aphios Corp, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Asana BioSciences LLC, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Aurobindo Pharma Ltd, AVEO Pharmaceuticals Inc, B Cell Design SAS, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene (Beijing) Co Ltd, Beijing Hanmi Pharmaceutical Co Ltd, BeyondSpring Pharmaceuticals Inc, Biocon Ltd, Bionomics Ltd, Bionovis SA, Biotecnol Ltd, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Burzynski Research Institute Inc, Calithera Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Carna Biosciences Inc, Cascadian Therapeutics Inc, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celleron Therapeutics Ltd, Celltrion Inc, Celyad SA, Chipscreen Biosciences Ltd, ChoDang Pharm Co Ltd, Chong Kun Dang Pharmaceutical Corp, Cipla Ltd, Cleave Biosciences Inc, Cleveland BioLabs Inc, COARE Biotechnology Inc, Coherus BioSciences Inc, Compugen Ltd, Conatus Pharmaceuticals Inc, Confluence Life Sciences Inc, Corvus Pharmaceuticals Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, Daiichi Sankyo Company Ltd, DanDrit Biotech A/S, Deciphera Pharmaceuticals LLC, Dicerna Pharmaceuticals Inc, Dr. Reddy's Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Company, Endor Nanotechnologies SL, EnGeneIC Ltd, Ensol Biosciences Inc, EntreChem SL, Enzene Biosciences Ltd, Enzo Biochem Inc, EpiThany Inc, Etubics Corp, Exelixis Inc, Exicure Inc, F-star Biotechnology Ltd, F. Hoffmann-La Roche Ltd, Formosa Laboratories Inc, Forty Seven Inc, Fusion Antibodies Ltd, Gene Techno Science Co Ltd, Genentech Inc, Genor BioPharma Co Ltd, Genoscience Pharma, Genzyme Corp, Gilead Sciences Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Glycostem Therapeutics BV, Glycotope GmbH, Green Cross Corp, Hadasit Medical Research Services & Development Ltd, Handok Inc, Hanmi Pharmaceuticals Co Ltd, Heat Biologics Inc, Hemispherx Biopharma Inc, Humorigin Biotechnology Corp, Hutchison China MediTech Ltd, iDD biotech SAS, Ideaya Biosciences Inc, Ignyta Inc, Ildong Pharmaceutical Co Ltd, Immodulon Therapeutics Ltd, ImmuneXcite Inc, Immunomedics Inc, Immunovative Therapies Ltd, Incanthera Ltd, Incyte Corp, Innovation Pharmaceuticals Inc, Innovent Biologics Inc, Inovio Pharmaceuticals Inc, Interprotein Corp, Intezyne Technologies Inc, Ionis Pharmaceuticals Inc, Isofol Medical AB, Jeil Pharmaceutical Co Ltd, JHL Biotech Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, KaloBios Pharmaceuticals Inc, Kancera AB, Karyopharm Therapeutics Inc, Kura Oncology Inc, Laboratorio ELEA SACIF y A, Lion Biotechnologies Inc, LipoMedix Pharmaceutical Inc, Lipopharma Therapeutics SL, Loxo Oncology Inc, Mabion SA, MacroGenics Inc, Mantis Therapeutics BV, Marina Biotech Inc, MediaPharma Srl, MedImmune LLC, Medinet Co Ltd, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Microlin Bio Inc, Molecular Partners AG, MolMed SpA, Mologen AG, Morphotek Inc, Multimmune GmbH, Mycenax Biotech Inc, NantKwest Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, Nektar Therapeutics, Neovacs SA, Nerviano Medical Sciences Srl, Nippon Kayaku Co Ltd, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Novogen Ltd, Noxxon Pharma AG, NuCana BioMed Ltd, OBI Pharma Inc, Omnitura Therapeutics Inc, Oncobiologics Inc, Oncology Research International Ltd, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Ono Pharmaceutical Co Ltd, Oryx GmbH & Co KG, Otsuka Holdings Co Ltd, Oxford BioMedica Plc, Pfizer Inc, Pharma Mar SA, PharmAbcine Inc, Pivotal BioSciences Inc, PlantForm Corp, Plexxikon Inc, PLx Pharma Inc, Precision Biologics Inc, Prima BioMed Ltd, Propanac Biopharma Inc, Provectus Biopharmaceuticals Inc, PsiOxus Therapeutics Ltd, Puma Biotechnology Inc, Puretech Health plc, Quintessence Biosciences Inc, R Pharm, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rgenix Inc, Rhizen Pharmaceuticals SA, Richter Gedeon Nyrt, Samumed LLC, Sanofi, Selvita SA, Siamab Therapeutics Inc, Sichuan Kelun Pharmaceutical Co Ltd, Sigma-Tau SpA, Sigmoid Pharma Ltd, Sillajen Biotherapeutics, Simcere Pharmaceutical Group, Sorrento Therapeutics Inc, Steba Biotech SA, Sumitomo Dainippon Pharma Co Ltd, SuviCa Inc, Symphogen A/S, SynDevRx Inc, Synermore Biologics Co Ltd, Taiho Pharmaceutical Co Ltd, TaiwanJ Pharmaceuticals Co Ltd, Takeda Pharmaceutical Company Ltd, Targovax ASA, Tarrex Biopharma Ltd, Tiltan Pharma Ltd, Tocagen Inc, TRACON Pharmaceuticals Inc, Transgene SA, United BioPharma Inc, Vaccinex Inc, VasGene Therapeutics Inc, Vaximm AG, ViiV Healthcare Ltd, Vitality Biopharma Inc, Wellstat Biologics Corp, Wilex AG, WntResearch AB, Wuhan YZY Biopharma Co Ltd, XBiotech Inc, XuanZhu Pharma Co Ltd, Yabao Pharmaceutical Group Co Ltd, Zymeworks In.
-The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology).
Purchase This Report at: https://goo.gl/ugM9nW.
Major Table of Content:
• Colorectal Cancer - Overview
• Colorectal Cancer - Therapeutics Development
• Colorectal Cancer - Therapeutics Assessment
• Colorectal Cancer - Companies Involved in Therapeutics Development
• Colorectal Cancer - Drug Profiles
• Colorectal Cancer - Dormant Projects
• Colorectal Cancer - Discontinued Products
• Colorectal Cancer - Product Development Milestones.
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Colorectal Cancer Pipeline Therapeutic Review H1 2017 here
News-ID: 612558 • Views: 651
More Releases from ReportsandReports
French Gaming Market 2020, Key Players, Demands, Trends, Growth Rate, Impact of …
French gaming market is estimated to reach US$13.16 billion in 2024, growing at a CAGR of 2.29% for the period spanning from 2020 to 2024. The factors such as rising number of smartphone users, increasing demand for internet of things, strong mobile gaming growth, growth of sports events and growing online sports betting are expected to drive the market. However, growth of the industry will be challenged by stringent government
Recent Analysis of Followspots Market | Robert Juliat, LYCIAN, Phoebus, Proel an …
Latest research report on "Followspots Market 2020 Global Research Report" now available at high quality database of deepresearchreports.com with market size, share, trends, competitive and statistical analysis. Get Free Sample PDF (including full TOC, Tables and Figures) of Followspots Market: https://www.deepresearchreports.com/contacts/request-sample.php?name=1198132 #Key Players- Robert Juliat, LYCIAN,Phoebus, Proel, GRIVEN, Coemar Lighting, Leviton, Teclumen and more. Market Segment by Type: - Discharge Lamp - Halogen Bulb - LED Lamp - Xenon Lamp - Others Market Segment by Application: - Concerts - Musicals -
Whipped Cream Dispensers Market to Witness Huge Growth by Key Players: Otis Clas …
Latest research report on "Whipped Cream Dispensers Market 2020 Global Research Report" now available at high quality database of deepresearchreports.com with market size, share, trends, competitive and statistical analysis. Get Free Sample PDF (including full TOC, Tables and Figures) of Whipped Cream Dispensers Market: https://www.deepresearchreports.com/contacts/request-sample.php?name=1198128 #Key Players- Otis Classic, ZOEMO, EurKitchen, Chef's Brand, Tesor, Mobright, Gorgeous, iSi Group and more. Market Segment by Type: Aluminum Dispenser Stainless Steel Dispenser Others Market Segment by Application: Restaurant Café Residence Others Ask For
Ventilators Market Grow By Leading Industry Players Philips Healthcare, ResMed I …
The report titled “Ventilators Market Report” sheds a concentrated focus on the Ventilators industry in terms of market driver, opportunities, restraints of global segmentation. Further data on the reports also includes demographic conditions, over-turning changing business cycles and analyzing country-to-market. Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3832180 Growth in this market is driven by the outbreak of the covid-19 pandemic, high prevalence of respiratory diseases, rapid growth in the geriatric population, increasing
More Releases for Bio
Global Bioplastics (Bio-plastics,Bio plastics) Market 2018 - Braskem, BASF
Apex Market Reports, recently published a detailed market research study focused on the “Bioplastics (Bio-plastics,Bio plastics) Market” across the global, regional and country level. The report provides 360° analysis of “Bioplastics (Bio-plastics,Bio plastics) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Bioplastics
Bio Electronics and Bio Sensors Market Forecasts, 2017-2025
Description: The global bio electronic market is valued USD $15 billion in 2016 and is expected to grow at a CAGR of 11.6% during the forecast period 2017-2025. The market is driven by various factors such as rapid advancement in semiconductor technology, high demand in implantable medical devices, increasing prevalence of neural and cardiac diseases among others. The emerging healthcare technologies such as lab on chip, ambulatory surgical centres, and personalized devices are
Bio Simulation Technology Market
Global Bio Simulation Technology Industry Bio Simulation Technology Market is estimated at $1.01 billion in 2015 and is projected to reach $2.99 billion by 2022 growing at a CAGR of 16.6% from 2015 to 2022. Reduction in the cost of drug discovery and development and risk of failure of drug molecule are some of the factors driving the market growth. Furthermore, R&D investments in biotechnology and pharmaceutical industries, growth in the
Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021
Qyresearchreports include new market research report “Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021″ to its huge collection of research reports. This market intelligence report serves its readers with an executive-level blueprint of the global Bio-Polyethylene Terephthalate (Bio-PET) market. Data from a number of paid and unpaid sources including press releases, journals, presentations, and white papers has been taken into account for collating this report. The various factors influencing the growth of
SHANE RADBONE CORPORATE BIO
Young, dynamic and highly successful Shane founded his own business, Executive Fitness Management at age 20 in 1991. After a successful career in football that took him as high as playing for Essendon, Shane appreciated the need to have more than just sport in his portfolio. However taking his on field attitude to the corporate arena, Executive Fitness Management (EFM) grew into Australia’s largest Corporate Fitness Company. It started with
The Bio-Chromatographers’ wish
Simply high dynamic binding capacities (DBC’s) are no longer sufficient. High DBC, at high flow rates with close to 100% recovery, across a wide range of molecular weights, this is what chromatographers look for in modern ion exchange resins. “BioPro” YMC’s hugely successful ion exchange material offers exactly this. The growing user base confirms very good separation, high dynamic binding capacities and excellent recoveries for the anion as well as